← All trials
NCT05425914
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2021
- Primary completion
- Mar 15, 2022
- Completion date
- Apr 30, 2022
- First posted
- Jun 21, 2022
- Last posted
- Jun 21, 2022
- Enrollment
- 108
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of FaisalabadLead sponsor
- University of FaisalabadOverall official - principal investigator
- University of FaisalabadReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.